Endologix (NASDAQ: ELGX) reported Q3 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $52.1 million versus the consensus estimate of $51.83 million.

GUIDANCE:

Endologix sees FY2016 revenue of $198-201 million, versus the consensus of $202 million.

For earnings history and earnings-related data on Endologix (ELGX) click here.